Bone Marrow Transplant (Autologous, MUD & Haplo)

Hematopoietic Stem Cell Transplantation (HSCT), commonly referred to as Bone Marrow Transplant (BMT), is a definitive curative treatment for multiple life-threatening hematological cancers and bone marrow disorders. Precision Cancer Research Institute (PCRI) provides comprehensive pre-transplant workup, donor identification, conditioning therapy oversight, and post-transplant long-term clinical care across all three major transplant categories.

Transplant Modalities Offered

• Autologous Stem Cell Transplant (Auto-BMT):

  The patient's own healthy peripheral blood stem cells are mobilized (using G-CSF/Plerixafor), harvested via apheresis, and cryopreserved. The patient then receives curative high-dose conditioning chemotherapy to eradicate residual microscopic malignancy, followed by re-infusion of their stored stem cells to rescue healthy bone marrow hematopoiesis. Primarily indicated for Multiple Myeloma, relapsed Hodgkin's Lymphoma, and Non-Hodgkin's Lymphoma (NHL).

• Matched Unrelated Donor (MUD) Transplant:

  When an HLA-matched sibling donor is unavailable, PCRI facilitates high-resolution molecular HLA typing and coordinated searches across national and international marrow donor registries (including DATRI, DKMS, and NMDP) to secure a 10/10 or 9/10 matched volunteer donor.

• Haploidentical (Half-Match) Transplant:

  A revolutionary advancement in modern BMT that removes the barrier of donor availability. Using advanced Post-Transplant Cyclophosphamide (PTCy) protocols, any first-degree family relative — parents, siblings, or biological children — who shares a 50% HLA match can serve as an immediate, life-saving donor.

Sterile Transplant Environment & Safety Infrastructure

• Positive-Pressure HEPA Filtration: Ultra-clean isolation rooms with >12 air exchanges per hour eliminating fungal spores and airborne pathogens during the neutropenic phase.
• Reverse Barrier Nursing: Chemotherapy-certified nurses dedicated to sterile central line maintenance, sterile dietary protocols, and protective isolation.
• Graft-Versus-Host Disease (GVHD) Management: Advanced immunosuppressive regimens and targeted biological interventions for acute and chronic GVHD.
• Infection Surveillance: Proactive PCR viral surveillance (CMV, EBV, BK virus), fungal prophylaxis, and round-the-clock emergency support.

Gallery